Jiangsu Maiwei Kang

Jiangsu Mywaykang Biotechnology is a clinical-stage biopharmaceutical company based in the China Medical City (CMC) in Taizhou, Jiangsu. The company specializes in the research, development, and industrialization of high-end recombinant protein drugs and innovative vaccines. Its core focus is addressing the clinical shortage of blood-derived products through the production of recombinant human serum albumin (rHSA). Mywaykang utilizes advanced protein expression and purification technologies to develop safer, scalable alternatives to traditional plasma-derived therapies and inactivated vaccines. The company's lead programs include a recombinant human serum albumin for critical care and a recombinant rabies vaccine.